CORXEL Bolsters Leadership Team with Seasoned CFO Kevin Xie to Drive Next Phase of Company Growth
NEW JERSEY/SHANGHAI, February 26, 2025 – Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today announced the appointment of Kevin Xie, PhD, as Chief Financial Officer. Kevin brings over two decades of healthcare investment and operational expertise to CORXEL, positioning the company for accelerated growth as it advances a leading pipeline of global cardiometabolic drug candidates. His appointment comes at a pivotal time as the company builds on its recent acquisition of CX11, a promising small molecule GLP-1 RA, aimed at addressing the global obesity epidemic and the start of the global registrational trial for JX10, an investigational drug for acute ischemic stroke with both thrombolytic and anti-inflammatory activities.
In his role as CFO, Kevin will oversee CORXEL's capital strategy, financial operations and investor relations. With a proven track record in scaling biotech ventures, Kevin most recently served as CFO of Gracell Biotechnologies, where he led the company through its Nasdaq IPO in 2021, multiple financing rounds, and its acquisition by AstraZeneca in 2024. Prior to Gracell, he held senior leadership roles at Fosun Group, Locust Walk Capital, Scopia Capital, and Great Point Partners, driving global healthcare investment and operational success.
"We are excited to welcome Kevin to the CORXEL team," said Sandy Mou, Board Executive Director and Chief Executive Officer of CORXEL." His deep expertise in strategic and operational finance, paired with his remarkable success in capital markets, will be critical as we propel the company into its next stage of growth. With Kevin's leadership, we are poised to maximize the potential of our lead candidates CX11 in obesity and JX10 for acute ischemic stroke, bringing us closer to delivering life-changing solutions for patients worldwide.”
Additional information
CORXEL, is a leading biotech company headquartered in US and China focused on developing innovative cardiometabolic therapies globally. CORXEL was founded in 2019 and has been committed to bringing innovative science and medicines to underserved patients around the world. With a strong and further developing asset pipeline, industry leading talent, and patient-centric focus, CORXEL is dedicated to delivering a meaningful and lasting impact on patients.
The portfolio of CORXEL consists of 3 assets with global rights and 2 assets with Greater China rights in late-stage clinical development. The portfolio with global rights covers CX11 for obesity and diabetes, JX10 for acute ischemic stroke (AIS) and JX09 for hypertension, while the portfolio with Greater China rights includes Etripamil and LNZ100.
For further information about CORXEL, please visit www.corxelbio.com
